Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

In the presentation before approval, cited above, Vertex estimated that there are 80 million acute pain patients in the US every year, of whom 40 million are prescribed opioids. 85,000 of these ...

ICER's evaluation of Vertex Pharmaceuticals' non-opioid pain drug, Journavx, finds cost-effectiveness related to potential ...

But it's logical to ask: What's Vertex's long-term story? Where will the company be in 10 years, for example? Let's find out. Image source: Getty Images. First, a bit of background on Vertex's CF ...

The aircraft were not visible in images taken on March 25 ... Garcia from the satellite imagery ABC News reviewed. MORE: US military strikes Houthi targets in Yemen "Additional squadrons and ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

And if you didn't stay up – or the weather conditions didn't cooperate – here's a rundown of photos so you can enjoy it with the masses. 32,355 people played the daily Crossword recently.